WW International, Inc. (WW)
NASDAQ: WW · Real-Time Price · USD
1.040
-0.020 (-1.89%)
At close: Oct 31, 2024, 4:00 PM
1.050
+0.010 (0.96%)
After-hours: Oct 31, 2024, 5:41 PM EDT
WW International Employees
WW International had 4,850 employees as of December 30, 2023. The number of employees decreased by 2,250 or -31.69% compared to the previous year.
Employees
4,850
Change (1Y)
-2,250
Growth (1Y)
-31.69%
Revenue / Employee
$171,020
Profits / Employee
-$76,090
Market Cap
82.92M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 30, 2023 | 4,850 | -2,250 | -31.69% |
Dec 31, 2022 | 7,100 | -600 | -7.79% |
Jan 1, 2022 | 7,700 | -2,300 | -23.00% |
Jan 2, 2021 | 10,000 | -7,000 | -41.18% |
Dec 28, 2019 | 17,000 | -1,000 | -5.56% |
Dec 29, 2018 | Pro | Pro | Pro |
Dec 30, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Jan 2, 2016 | Pro | Pro | Pro |
Jan 3, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
FAT Brands | 7,390 |
FAT Brands | 7,390 |
Superior Industries International | 6,600 |
Yatra Online | 1,268 |
Kewaunee Scientific | 1,006 |
Allbirds | 927 |
GAN Limited | 677 |
Canoo | 651 |
WW News
- 8 days ago - WW International, Inc. Schedules Third Quarter 2024 Earnings Conference Call - GlobeNewsWire
- 22 days ago - WeightWatchers stock price skyrockets on news that it will offer a compounded GLP-1 weight-loss drug like Wegovy - Fast Company
- 22 days ago - WW Stock Rises as WeightWatchers Expands Drug Offerings - GuruFocus
- 22 days ago - WW International (WW) Surges After Adding Semaglutide to Weight Loss Program - GuruFocus
- 22 days ago - WW International (WW) Surges After Introducing Compounded Semaglutide to Weight Loss Plans - GuruFocus
- 23 days ago - WeightWatchers Stock Soars on Copycat Weight-Loss Drug Offering - Investopedia
- 23 days ago - WeightWatchers' stock soars after adding compounded GLP-1 treatment to its offering - Market Watch
- 23 days ago - WeightWatchers adds compounded version of Novo's obesity drug to weight-loss program - Reuters